Risperdal Lawsuit Plaintiffs Are Encouraged By Multiple Plaintiff Wins In Prior Trials Against Johnson & Johnson

LegalHerald.com comments on reports stating that of four trials referencing Risperdal, which took place last year, three have been won by plaintiffs. It has been noted that juries in Philadelphia have found defendant Janssen Pharmaceuticals (a subdivision of Johnson & Johnson and manufacturer of Risperdal) neglected to provide sufficient warnings to the public regarding potential links from Risperdal use and the development of gynecomastia in men.

Gynecomastia is a medical condition which can cause males to develop substantial and abnormal amounts of breast tissue. To plaintiffs currently awaiting trial, a three out of four trial plaintiff win is good news. As they await further legal proceedings, they are hopeful for similar outcomes and observant of finished trial results.

One of these trial results showed an outcome in which the plaintiff was awarded $500,000, after reportedly taking Risperdal from 2006-2009 in order to combat issues from Tourette Syndrome. He began using the drug at age 11 in 2006, when it suddenly became FDA-approved for use in children. After taking the antipsychotic drug for just one year’s time, at age 12, the young boy began to develop breasts. He claims to have suffered emotional abuse and bullying at school, and finally underwent breast reduction surgery at the age of 18.

Another young man was awarded $2.5 million from a jury after heading to court. He reportedly used Risperdal in 2002 in order to manage mood swings. He alleged that due to his use of the drug, he developed severe gynecomastia, to the extent where he developed size 46-DD breasts. During this trial, a Johnson & Johnson biochemist took the stand and testified that the corporate giant was aware of the potential risk of male breast development, but had chosen to conceal this fact.

In a third risperdal lawsuit, a young man was awarded $1.7 million by the jury for his mental anguish and physical disfigurement. He reportedly used the drug to treat his schizophrenia at the young age of 9. This was during a time where Risperdal use was not FDA-approved to treat children, and therefore the information in this case was especially notable.

Today, it has been reported that Johnson & Johnson is now facing around 1,600 other lawsuits. Attorneys believe that these prior Risperdal trial losses may result in a decision by the company to make a mass settlement offer. The future lawsuits are currently awaiting trial dates and have been centralized in a Philadelphia court.

As additional lawsuit allegations continue to surface, the public understandably becomes increasingly concerned. The attorneys of Banville Law are working to help others who have used Risperdal and who believe that it has caused them adverse events. Affected patients may be entitled to significant compensation, and are encouraged to explore their legal rights in full. To help those wishing to further investigate their options, the attorneys of Banville Law are currently offering free legal consultations to qualified individuals.

To request additional Risperdal lawsuit information, or to ask questions, please contact the attorneys of Banville Law by calling 888-997-3792.